CA2603359A1 - Mimeticorps de la glp-1 humaine, compositions, procedes et utilisations - Google Patents

Mimeticorps de la glp-1 humaine, compositions, procedes et utilisations Download PDF

Info

Publication number
CA2603359A1
CA2603359A1 CA002603359A CA2603359A CA2603359A1 CA 2603359 A1 CA2603359 A1 CA 2603359A1 CA 002603359 A CA002603359 A CA 002603359A CA 2603359 A CA2603359 A CA 2603359A CA 2603359 A1 CA2603359 A1 CA 2603359A1
Authority
CA
Canada
Prior art keywords
glp
seq
mimetibody
drug
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002603359A
Other languages
English (en)
Inventor
Karyn T. O'neil
Kristen Picha
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2603359A1 publication Critical patent/CA2603359A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/605Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2318/00Antibody mimetics or scaffolds
    • C07K2318/10Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA002603359A 2005-03-28 2005-12-22 Mimeticorps de la glp-1 humaine, compositions, procedes et utilisations Abandoned CA2603359A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2005097175 2005-03-28
USPCT/US2005/097175 2005-03-28
PCT/US2005/046884 WO2007081302A2 (fr) 2005-03-28 2005-12-22 Miméticorps de la glp-1 humaine, compositions, procédés et utilisations

Publications (1)

Publication Number Publication Date
CA2603359A1 true CA2603359A1 (fr) 2007-07-19

Family

ID=38256744

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002603359A Abandoned CA2603359A1 (fr) 2005-03-28 2005-12-22 Mimeticorps de la glp-1 humaine, compositions, procedes et utilisations

Country Status (12)

Country Link
EP (1) EP1871811A4 (fr)
JP (1) JP2008546373A (fr)
KR (1) KR20080005378A (fr)
CN (1) CN101389346A (fr)
AU (1) AU2005339797A1 (fr)
BR (1) BRPI0520168A2 (fr)
CA (1) CA2603359A1 (fr)
CR (1) CR9481A (fr)
IL (1) IL186307A0 (fr)
MX (1) MX2007011975A (fr)
NO (1) NO20075272L (fr)
WO (1) WO2007081302A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200843794A (en) * 2006-12-21 2008-11-16 Centocor Inc Use of long-acting GLP-1 receptor agonists to improve insulin sensitivity and lipid profiles
CN111574583B (zh) * 2020-04-10 2021-06-25 上海海路生物技术有限公司 蛋白复性试剂及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6656728B1 (en) * 1999-02-08 2003-12-02 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
ES2311560T3 (es) * 2000-12-07 2009-02-16 Eli Lilly And Company Proteinas de fusion glp-1.
JP2006504406A (ja) * 2002-06-28 2006-02-09 セントカー・インコーポレーテツド 哺乳動物のch1欠失ミメティボディ、組成物、方法および使用
EP1575499A2 (fr) * 2002-06-28 2005-09-21 Centocor, Inc. Corps mimetiques d'epo de mammifere a deletion ch1, compositions, methodes et utilisations associees
WO2005005604A2 (fr) * 2003-06-30 2005-01-20 Centocor, Inc. Proteines derivees de l'immunoglobuline anti-cible et genetiquement modifiees, compositions, procedes et utilisations
EA011583B1 (ru) * 2004-03-31 2009-04-28 Сентокор, Инк. Миметические антитела glp-1 человека, композиции, способы и применения

Also Published As

Publication number Publication date
AU2005339797A1 (en) 2007-07-19
MX2007011975A (es) 2008-03-14
NO20075272L (no) 2007-12-28
CR9481A (es) 2009-01-14
EP1871811A2 (fr) 2008-01-02
CN101389346A (zh) 2009-03-18
BRPI0520168A2 (pt) 2009-04-22
IL186307A0 (en) 2008-01-20
EP1871811A4 (fr) 2009-07-22
WO2007081302A3 (fr) 2008-11-13
WO2007081302A2 (fr) 2007-07-19
JP2008546373A (ja) 2008-12-25
KR20080005378A (ko) 2008-01-11

Similar Documents

Publication Publication Date Title
US8071103B2 (en) Pharmaceutical composition comprising a human GLP-1 mimetibody
US20070128193A1 (en) GLP-1 agonists, compositions, methods and uses
US20070135338A1 (en) Human GLP-1 mimetibodies, compositions, methods and uses
US7241733B2 (en) Mammalian EPO mimetic CH1 deleted mimetibodies, compositions, methods and uses
AU2004277884B2 (en) Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
WO2004002417A2 (fr) Corps mimetiques mammaliens a deletion ch1, compositions, procedes et utilisations
CA2673657A1 (fr) Utilisation d'agonistes du recepteur glp-1 a action prolongee pour ameliorer la sensibilite a l'insuline et les profils des lipides
CA2603359A1 (fr) Mimeticorps de la glp-1 humaine, compositions, procedes et utilisations

Legal Events

Date Code Title Description
FZDE Discontinued